PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novel Vaccines Improve Potential for European Vaccines Manufacturers - The vaccines market, which was earlier associated with low profit margins and slow growth rates, has gained momentum in recent years through innovation
Novel Vaccines Improve Potential for European Vaccines Manufacturers

 

NewswireToday - /newswire/ - London, United Kingdom, 2009/01/14 - The vaccines market, which was earlier associated with low profit margins and slow growth rates, has gained momentum in recent years through innovation.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The introduction of novel vaccines for diseases with high burden and continuous investments aimed at boosting production capacity is driving the growth of this previously unattractive market.

New analysis from Frost & Sullivan (pharma.frost.com), European Vaccines Market, finds that the market earned revenues of $4.50 billion in 2007 and estimates this to reach $9.85 billion in 2014.

“Health authorities are prepared to spend on prevention, rather than witness expenditures on vaccine-preventable diseases spiral out of control,” notes Frost & Sullivan Research Analyst John Paul. “The growing support for vaccinations from physicians and paediatricians has been fundamental to the growth of the vaccines market.”

The market has shown remarkable growth in recent years as a result of the introduction of vaccines in untapped disease segments. Governments’ acceptance and reimbursement of such efficient, albeit expensive, vaccines has encouraged market participants to increase investments in R&D and develop innovative and differentiated products. Innovation in technology has enabled manufacturers to move ahead into promising areas like therapeutic vaccines where the potential for growth is unlimited.

However, Europe is already at a disadvantage because of the ban on direct-to-consumer marketing. Uptake levels in Europe remain slower than in the US market. In addition to the inherent challenges in vaccine manufacture and R&D, market participants also have to deal with government policies, perceptions and awareness levels that diverge widely across Europe.

“A clear comprehension about the dynamics in various regions is important to predict demand and alter business strategies accordingly,” explains Paul. “Predicting and meeting demand is one of the most challenging factors in the vaccines industry. Efficiency in manufacturing and distribution has to be achieved in order to offset limited production capacities and low profit margins.”

Keeping abreast of epidemiological trends and government policies, coupled with efforts to boost physician and public awareness, will be crucial. In the context of R&D, the identification of the disease areas to be targeted, through a vaccine or a combination, is important because market penetration and revenue generation are largely dependent upon these factors in various regions.

“Vaccine manufacturers should be able to identify key market dynamics, promote efficiency of operation and support public perception while adapting and implementing lean principles and innovative marketing strategies,” advises Paul. “Streamlining investments into R&D of adjuvant technologies, therapeutic and DNA vaccines could enable realisation of significant potential in these areas.”

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European vaccines market, then send an email to Katja Feick, Corporate Communications, at katja.feick[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

European Vaccines Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Services Programme, which also includes research in the following markets: European Therapeutic Monoclonal Antibody Markets, European Human Growth Hormones Market, European Pharma/biotech Contract Manufacturing Markets: A Strategic Outlook and European Drug Delivery Markets - Opportunity Analysis. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents.

European Vaccines Market
M276

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novel Vaccines Improve Potential for European Vaccines Manufacturers

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Katja Feick 
+49 (0) 69 77 0 33 43 katja.feick[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)